We found that pCR rates were significantly higher in the “Immunity high” subgroup in HER2-negative/ER-positive (16.7% versus 8.4%, OR = 2.17, p = 0.05), HER2-positive (43.6% versus 16.7%, OR = 3.84, p = 0.01), and TNBC breast cancers (37.3 versus 22.6%, OR = 2.08, p = 0.03) (S3A Fig). This evidence concerns the gene ESR1 and breast cancer.